BCAL Diagnostics (BDX) Stock Price, News & Analysis

Company Overview

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $36.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BDX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of BCAL Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BCAL Diagnostics investors own include Chevron (CVX), JPMorgan Chase & Co. (JPM), Bristol-Myers Squibb (BMY), 3M (MMM), NextEra Energy (NEE), ONEOK (OKE) and Tesla (TSLA).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: Medical Equipment
• Current Symbol: ASX:BDX
• CIK: N/A
• Web: www.bd.com
• Phone: 12018476800
• Fax: N/A
• Employees: 77,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.40 million
• Net Margins: -295.31%
• Pretax Margin: N/A
• Return on Equity: -87.34%
• Return on Assets: -36.51%

Debt

• Debt-to-Equity Ratio: 17.74
• Current Ratio: 3.60
• Quick Ratio: 6.70

Sales & Book Value

• Annual Sales: $3.10 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.03 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 358,660,000
• Free Float: N/A
• Market Cap: $36.60 million
• Optionable: Not Optionable
• Beta: 0.69